FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023331812> ?p ?o ?g. }

• W2023331812 endingPage "1429" @default.
• W2023331812 startingPage "1423" @default.
• W2023331812 abstract "Cyclooxygenase-2 (COX-2) seems to be involved at various steps in the processes of malignant transformation and tumor progression. Investigations have shown that COX-2 overexpression is associated with increased proliferation, reduced apoptosis, and angiogenesis.Specimens from 125 patients with high-grade, advanced-stage (Stage III-IV) serous ovarian carcinoma were evaluated by immunohistochemistry for COX-2, p53, bcl-2, epidermal growth factor receptor (EGFR), and Her-2/neu expression and for CD34-stained microvessel density (MVD). Statistical analysis was performed to investigate the correlations between COX-2 expression and 1) clinicopathologic characteristics, 2) tumor MVD, and 3) expression of other molecular markers. The effect of COX-2 expression on survival was determined using survival analysis.Increased COX-2 expression was significantly correlated with tumor MVD (Spearman rank correlation test: r = 0.41; P < 0.001). There was no association observed between COX-2 expression and expression levels of EGFR, Her-2/neu, bcl-2, or p53. Patients who had tumors that showed high COX-2 expression had a worse prognosis compared with patients who had tumors with low expression (death hazard ratio, 2.0; 95% confidence interval, 1.2-3.5; P < 0.001). A multivariate analysis revealed that COX-2 expression was the strongest predictor of survival among the different prognostic factors analyzed.The current study demonstrated that COX-2 expression was correlated significantly with survival in patients with high-grade, high-stage serous ovarian carcinoma. Expression of COX-2 also was correlated with tumor angiogenesis but not with EGFR, Her-2/neu, or p53 expression. In addition to their prognostic significance, a better understanding of the biology of these molecular changes may help identify new targets for therapy in patients with ovarian carcinoma." @default.
• W2023331812 created "2016-06-24" @default.
• W2023331812 creator A5003299608 @default.
• W2023331812 creator A5005251596 @default.
• W2023331812 creator A5019764947 @default.
• W2023331812 creator A5033425459 @default.
• W2023331812 creator A5036827926 @default.
• W2023331812 creator A5054168065 @default.
• W2023331812 creator A5082224419 @default.
• W2023331812 date "2003-09-18" @default.
• W2023331812 modified "2023-10-10" @default.
• W2023331812 title "The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma" @default.
• W2023331812 cites W1965578044 @default.
• W2023331812 cites W1967526789 @default.
• W2023331812 cites W2011102961 @default.
• W2023331812 cites W2017116566 @default.
• W2023331812 cites W2035080371 @default.
• W2023331812 cites W2045032599 @default.
• W2023331812 cites W2058526541 @default.
• W2023331812 cites W2058551552 @default.
• W2023331812 cites W2058559637 @default.
• W2023331812 cites W2070995329 @default.
• W2023331812 cites W2107833029 @default.
• W2023331812 cites W2111439621 @default.
• W2023331812 cites W2127558096 @default.
• W2023331812 cites W2133620160 @default.
• W2023331812 cites W2152943473 @default.
• W2023331812 cites W2318925269 @default.
• W2023331812 cites W4235899006 @default.
• W2023331812 doi "https://doi.org/10.1002/cncr.11650" @default.
• W2023331812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14508829" @default.
• W2023331812 hasPublicationYear "2003" @default.
• W2023331812 type Work @default.
• W2023331812 sameAs 2023331812 @default.
• W2023331812 citedByCount "70" @default.
• W2023331812 countsByYear W20233318122012 @default.
• W2023331812 countsByYear W20233318122013 @default.
• W2023331812 countsByYear W20233318122014 @default.
• W2023331812 countsByYear W20233318122015 @default.
• W2023331812 countsByYear W20233318122017 @default.
• W2023331812 countsByYear W20233318122019 @default.
• W2023331812 countsByYear W20233318122021 @default.
• W2023331812 countsByYear W20233318122023 @default.
• W2023331812 crossrefType "journal-article" @default.
• W2023331812 hasAuthorship W2023331812A5003299608 @default.
• W2023331812 hasAuthorship W2023331812A5005251596 @default.
• W2023331812 hasAuthorship W2023331812A5019764947 @default.
• W2023331812 hasAuthorship W2023331812A5033425459 @default.
• W2023331812 hasAuthorship W2023331812A5036827926 @default.
• W2023331812 hasAuthorship W2023331812A5054168065 @default.
• W2023331812 hasAuthorship W2023331812A5082224419 @default.
• W2023331812 hasBestOaLocation W20233318121 @default.
• W2023331812 hasConcept C10515644 @default.
• W2023331812 hasConcept C121608353 @default.
• W2023331812 hasConcept C126322002 @default.
• W2023331812 hasConcept C142724271 @default.
• W2023331812 hasConcept C143998085 @default.
• W2023331812 hasConcept C146357865 @default.
• W2023331812 hasConcept C150173356 @default.
• W2023331812 hasConcept C151730666 @default.
• W2023331812 hasConcept C181199279 @default.
• W2023331812 hasConcept C204232928 @default.
• W2023331812 hasConcept C207103383 @default.
• W2023331812 hasConcept C2777546739 @default.
• W2023331812 hasConcept C2777632260 @default.
• W2023331812 hasConcept C2779689624 @default.
• W2023331812 hasConcept C2780394083 @default.
• W2023331812 hasConcept C2780427987 @default.
• W2023331812 hasConcept C3019054536 @default.
• W2023331812 hasConcept C44249647 @default.
• W2023331812 hasConcept C502942594 @default.
• W2023331812 hasConcept C50382708 @default.
• W2023331812 hasConcept C55493867 @default.
• W2023331812 hasConcept C71924100 @default.
• W2023331812 hasConcept C86803240 @default.
• W2023331812 hasConceptScore W2023331812C10515644 @default.
• W2023331812 hasConceptScore W2023331812C121608353 @default.
• W2023331812 hasConceptScore W2023331812C126322002 @default.
• W2023331812 hasConceptScore W2023331812C142724271 @default.
• W2023331812 hasConceptScore W2023331812C143998085 @default.
• W2023331812 hasConceptScore W2023331812C146357865 @default.
• W2023331812 hasConceptScore W2023331812C150173356 @default.
• W2023331812 hasConceptScore W2023331812C151730666 @default.
• W2023331812 hasConceptScore W2023331812C181199279 @default.
• W2023331812 hasConceptScore W2023331812C204232928 @default.
• W2023331812 hasConceptScore W2023331812C207103383 @default.
• W2023331812 hasConceptScore W2023331812C2777546739 @default.
• W2023331812 hasConceptScore W2023331812C2777632260 @default.
• W2023331812 hasConceptScore W2023331812C2779689624 @default.
• W2023331812 hasConceptScore W2023331812C2780394083 @default.
• W2023331812 hasConceptScore W2023331812C2780427987 @default.
• W2023331812 hasConceptScore W2023331812C3019054536 @default.
• W2023331812 hasConceptScore W2023331812C44249647 @default.
• W2023331812 hasConceptScore W2023331812C502942594 @default.
• W2023331812 hasConceptScore W2023331812C50382708 @default.
• W2023331812 hasConceptScore W2023331812C55493867 @default.
• W2023331812 hasConceptScore W2023331812C71924100 @default.
• W2023331812 hasConceptScore W2023331812C86803240 @default.

• next